The lungs are involved so frequently with rheumatologic problems. This issue will cover Radiology of lung disease in the rheumatic diseases, Histopathology of lung disease in the rheumatic diseases, Determining respiratory impairment, Lung disease in RA, Lung disease in scleroderma, and many more!

Malpractice settlements are large for undetected hydroxychloroquine and chloroquine toxicity which, if untreated, can lead to permanent loss of central vision. Knowledge of the ocular toxicity of these drugs has increased during the past fifty years as their use has expanded. Hydroxychloroquine and Chloroquine Retinopathy is the first single-source book on the subject and is essential for the practicing ophthalmologists, rheumatologists, dermatologists, and internists who prescribe these drugs. It covers clinical topics such as signs and symptoms of toxicity, toxicity screening, ancillary testing, to whom and why the drugs are prescribed and dosing considerations. Additionally, the book addresses practice management considerations, including coding, reimbursement and equipment costs, and the medico-legal responsibilities of the rheumatologist and of the ophthalmologist. Guidelines for the management of hydroxychloroquine and chloroquine vary around the world and differences between the guidelines of the United Kingdom, the United States, and other countries are identified. The book concludes with a collection of case examples illustrating common clinical scenarios and their management. This book is a "must-have" resource for physicians who use these drugs.

The ability to intervene at the earliest phases in the pathogenesis of a chronic rheumatic disease caused by auto-inflammatory, autoimmune, or tissue injury mechanisms has th epotential to prevent disease manifestations and consequences, limited loss of quality of life, comorbidity, and costs to society. This issue is dedicated to exploring the stages of rheumatic disease, biologic mechanisms contributing to the pathogenesis along with possible ways to study and screen for persons at risk with the ultimate goal of finding ways to prevent these devastating diseases.

This issue brings the rheumatologist on the current thinking on treatment of Systemic Lupus Erythematosus, with an eye to the future. Topics covered include B cell biology and related therapies; glutamate receptor biology and its clinical significance in neuropsychiatric SLE; platelet C4d and vascular complications; biomarkers in lupus nephritis; endothelial function and its implications for cardiovascular and renal disease in SLE; changing worldwide epidemiology of SLE and its relationship to environmental, ethnic, and other sociodemographic factors; work loss, disability, quality of life, and compliance in SLE; pediatric lupus; metabolic syndrome and related endocrine abnormalities; the significance of interferon and the consequences of anti-interferon in SLE; and cutaneous lupus and the CLASI instrument.

Gout is now the most common form of inflammatory arthritis in the United States, with a recent resurgence of research interest in its cause and management. Calcium crystal-related arthritis has also attracted renewed attention, with new nomenclature having been recently elaborated, aiding contemporary research efforts. This topic has never been covered in Rheumatic Disease Clinics and it represents a large content hole. The articles will cover diagnosis, management, emerging therapies and imaging.

With the FDA release of the drug Uloric in 2009, the research and interest around gout and crystal arthropathies has exploded. Gout affects over 8 million Americans. The gout rate was 7% among Americans aged 60 to 79 in the early 1990s, compared with 9% by 2008. Among those aged 80 and older, the rate more than doubled, from 6% to 13% over the nearly 20-year time span. This topic has never been covered in Rheumatic Disease Clinics and it represents a large content hole. The articles will cover diagnosis, management, emerging therapies and imaging

Ibuprofen is one of the most successful drugs used worldwide for the treatment of mild to moderate pain and various inflammatory conditions. Over the past 40 years, ibuprofen has been proven to be as safe or even safer and also as effective as the established non-steroidal anti-inflammatory drugs (NSAIDs) and the coxibs. This well-written book reviews the pharmacology, clinical uses and the various adverse effects of Ibuprofen, the disposition and unique modes of action in relation to clinical effects of the drug as well as various formulations. The use of combinations with other drugs (e.g. paracetamol, codeine, caffeine) are critically assessed and the impact of natural products and Chinese Medicines on the safety of ibuprofen.

Congenital hip disease (CHD) is the main cause of secondary osteoarthritis (OA) of the hip in young adults, which accounts for almost 40% of all cases of hip OA. Total hip replacement (THR) performed using optimal techniques can achieve a radical improvement in the quality of life of adult patients. This book offers in-depth coverage of all aspects of CHD in adults and its treatment. Relevant information is first provided on the basic anatomy of the hip and OA of the hip and on the classification, epidemiology, and natural history of CHD. The now limited role of femoral and pelvic osteotomies is carefully evaluated, and the use of THR is then considered in detail. Indications and preoperative planning are discussed, and the available operative techniques, analyzed. Clear guidance is provided on overcoming major technical difficulties, and the benefits of particular approaches and techniques are highlighted. More than 180 images and numerous case studies complement this reader-friendly text. The book will be an invaluable tool for orthopedic surgeons, rheumatologists and radiologists.

This issue of Rheumatic Disease Clinics teaches you the latest best practices for using musculoskeletal ultrasound to diagnose and monitor the progression of rheumatoid arthritis, vasculitis, and other rheumatic and soft tissue disorders.

This book explores comorbidity in patients with rheumatic diseases and details both care and treatment options in standard clinical practice. Patients with rheumatic diseases are clinically complex, and the interplay of their disease activity with associated conditions may lead to increased morbidity and mortality. Recently there have been major advances in the management of rheumatic diseases, however, without addressing the potential comorbid conditions, including cardiovascular disease; pulmonary disease; and depression; outcomes remain poor. With its 19 chapters, covering the management of major rheumatic diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus , and osteoarthritis), potential comorbidities and treatment recommendations, as well as possible interactions between conditions; this book addresses the gap between textbook medicine and day to day patients' care. Authors also discuss the new hot issue of the comorbidity index, comparing the standard tools to the recently developed indices and how they can assist the rheumatologists in determining disease burden, prognosis, and comorbidity probability. This book is an ideal clinical guide and reference that enables rheumatologists, internal medicine physicians, and residents to address the full clinical expression of these rheumatic diseases with views towards prevention or early management of comorbid conditions.

Guest edited by Jonathan Kay, this issue of Rheumatic Disease Clinics will cover the latest research and evidence surrounding the diagnosis, treatment and management of rarely seen rheumatic diseases.

Osteoarthritis is the leading cause of disability among older adults affecting upward of 1 in 8 adults. This issue will cover epidemiology, imaging, disease management and modification, and many more topics.

Literally thousands of papers have been published on nitric oxide over the past ten years. But there is no single monograph available that has previously attempted to summarize the important features of the roles of nitric oxide in inflammation. The voluminous literature regarding the incredible range of chemical and biological effects of nitric oxide and reactive nitrogen oxide species, RNOS, may present a tangle of confusing information to the researcher. This volume brings together experts from nitric oxide and inflammation research and presents a concise up-to-date overview as well as future aspects of this rapidly growing field.

Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today--drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.

To ensure the best possible clinical outcomes for arthritis patients, it is essential that they be seen early and treated appropriately at the earliest opportunity.? Early therapy has proven much more effective than that given late.? This issue of Rheumatic Disease Clinics of North America brings the rheumatologist up to date on the latest treatments and interventions in evolving arthritis and established early arthritis.? Topics covered include early rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, oligoarthritis, osteoarthritis, and others.? Imaging modalities are addressed as well as various contemporary treatments including biologics.

Total joint replacement is an effective procedure, resulting in decreased pain and improved function and quality of life in patients of all age groups including the elderly. The use of TJR is increasing and therefore this issue reviews topics such as patient satisfaction with total joint arthroplasty, patient reported outcomes, rehabilitation with total joint arthroplasty, minimally Invasive total joint arthroplasty, and peri-operative complications of total joint arthroplasty.

Edited by Drs. Juergen Braun and Joachim Sieper, this issue of Rheumatic Disease Clinics comprehensively reviews the state of the art of spondyloarthritis (SpA) diagnosis, prognosis, pathogenesis and genetic insights, and treatment. The worldwide burden of SpA now exceeds that of rheumatoid arthritis. General topics covered include inflammatory back pain, pathophysiology, imaging techniques, and therapeutic strategies.

The Guest Editors have assembled international experts in rheumatology to present an update to pediatricians. The basics are covered, including an article on the principles of inflammation in the child and one on the approach to the child with joint inflammation. From there, specifics are presented in the following articles: Laboratory Testing in Rheumatology; Rheumatologic Emergencies in newborns, children and adolescents; Juvenile Idiopathic Arthritis; Macrophage Activation Syndrome; Systemic Lupus Erythematosus; Idiopathic Inflammatory Myopathies in Childhood; Scleroderma; Vasculitis; Kawasaki disease; Autoinflammatory diseases; Approach to the patient with non-inflammatory? musculoskeletal pain; and Immune deficiency diseases with rheumatic manifestations.

This issue features internationally renowned experts who have provided their expertise on a variety of topics related to the importance of vitamin D.? It was not until feed back loops were identified between Vitamin D production and parathyroid hormone, phosphate that it earned its place as a true endocrine hormone. Current social and economic conditions have brought it back into the limelight with outbreaks of rickets and osteomalacia even in developed countries. However its complex regulation, together with the identification and characterization of the vitamin D receptor and its role in influencing multiple genetic pathways and function has heralded a new era highlighting its importance in health and disease. This includes its role in auto immune diseases such as multiple sclerosis, diabetes mellitus, cancer especially breast and prostate, skin, neurological and cognitive disorders and infectious diseases such as tuberculosis. We now know that adequate levels of vitamin D it is important in preventing falls and fracture.? The need for supplementation and the amount recommended has also changed considerably from what we previously considered sufficient.? The ongoing development of selective active analogs of vitamin D targeted to specific organs and function leads to the exciting possibility of? improving outcomes of diseases associated with vitamin D regulation.

The International Congress on Antiphospholipid Antibodies is held every three years to discuss the recent advances and future directions in Antiphospholipid Syndrome (APS). This volume collects the scientific highlights and new findings about APS that were generated from the most recent 13th Congress, held in Galveston, Texas in 2010. Chapters were written by an internationally-distinguished group of scientists from the point-of-view of multiple specialty areas. Each chapter was written in a uniform and systematic basis to present the latest evidence-based research, including the basic science of APS, task force reports from the Congress on controversial aspects of APS, and future directions of APS research. This book will appeal to all clinicians involved in the treatment and management of APS patients, to residents in a variety of medical subspecialties, and to research scientists interested in a better understanding of this complex and evolving disease.

This timely and evocative issue of Rheumatic Disease Clinics explores important current and controversial topics in the treatment of osteoporosis.? And it answers some tough questions ? Here are some examples.? How long do I treat my patient Is there a place for bone turnover markers How much Vitamin D should I recommend Controversies around calcium and Vitamin D are explored regarding the coronary risk and pancreatic issues.? Emerging therapies are presented, including sclerostin and oral calcitonin.? Long-term safety concerns of antiresporptive therapy (ONJ, atypical fracture, would healing) are explained.? The utility and limitations of FRAX are covered, as well as Prolia and the RANKL pathway.? An update on glucocorticoid induced OP is given.? The reader is also brought up to date on men's health issues and OP.? This is an essential issue for any practicing rheumatologist to stay current in the field.

This issue of Rheumatic Disease Clinics of North America provides foundational and in-depth information about paraneoplastic and cancer treatment-related rheumatic disorders, in which every practicing rheumatologist should be well-versed.? Topics covered include neoplasm risk in patients with rheumatic diseases; neoplasm risk of anti-rheumatic therapy; rheumatologic laboratory findings in malignancy; rheumatic manifestations of primary and metastatic bone tumors and paraneoplastic bone disease; neoplastic/paraneoplastic synovitis; neoplastic/paraneoplastic dermatitis, fasciitis, and panniculitis; neoplastic/paraneoplastic vasculitis, vasculopathy, and hypercoagulability; neoplastic/paraneoplastic myalgias and myositis; and less-common neoplastic/paraneoplastic syndromes.